Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.86 USD -0.03 ( 0.77%)
Last update at 2026-11-06T21:00:00Z
VOLUME
103086
Market Cap
87.83M

Momentum Score

…

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.84
Low
4.00
High
52 Week Price Range
1.82
Low
3.09
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Oramed Pharmaceuticals is a clinical-stage company developing an oral protein/peptide delivery platform, led by an oral insulin capsule for type 2 diabetes and additional peptide candidates. The company may benefit from demand for non‑injectable diabetes treatments and from platform licensing or clinical success that could support long-term growth.

Key risks are clinical and regulatory failure, cash burn and dilution, competition from established insulin and emerging oral peptide products, and manufacturing and commercialization scale-up.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.89
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
2.70M
Debt / Equity
0.32
ROE
-12.40%
Net Debt
42.57M
ROCE
-8.54%
Diluted EPS TTM
-0.71

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2023-08-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-08-31 2022-12-31 2022-08-31
Income before tax -15.92M 5.09M -37.66M -37.66M -37.66M
Minority interest 0.04M 0.44M - 1.20M 1.20M
Net income -19.06M 5.53M -37.76M -37.76M -36.56M
Selling general administrative 6.46M 8.43M 13.81M 13.81M 15.66M
Selling and marketing expenses - 0.29M 1.85M 1.85M -
Gross profit - 1.34M 2.70M 2.70M -
Reconciled depreciation 0.19M 0.20M - 0.06M 0.06M
Ebit - -15.77M -40.60M -40.60M -40.60M
Ebitda - -15.57M -36.98M -36.98M -37.61M
Depreciation and amortization - 0.20M 3.62M 3.62M -
Operating income -12.78M -15.77M -40.60M -40.60M -40.60M
Other operating expenses - 17.11M 43.30M 43.30M -
Interest expense 0.85M 3.58M 2.93M 2.93M 0.00M
Tax provision 3.18M 0.00M - 0.10M 0.10M
Interest income 5.00M 8.03M - 3.57M 3.57M
Net interest income 4.10M 4.59M - 3.56M 3.56M
Income tax expense - - 0.10M 0.10M 0.10M
Total revenue 0.00M 1.34M 2.70M 2.70M 2.70M
Total operating expenses 12.78M 17.11M 43.30M 43.30M 43.30M
Total other income expense net -7.24M 20.86M 2.93M 2.93M -0.63M
Net income from continuing ops -19.10M 5.09M - -37.76M -37.76M
Net income applicable to common shares - - - - -36.56M
Breakdown 2024-12-31 2023-12-31 2023-08-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-08-31 2022-12-31 2022-08-31
Total assets 155.28M 220.55M 161.64M 161.64M 0.00M
Other current assets 1.29M 0.54M 1.39M 1.39M 0.12M
Total liab 9.93M 57.66M 10.49M 10.49M 0.01M
Total stockholder equity 146.26M 163.82M 151.81M 151.81M 0.15M
Other current liab - 1.38M 1.98M -0.19M 0.00M
Common stock - 0.48M 0.48M 0.48M 0.00M
Capital stock 0.48M 0.48M - 0.48M 0.48M
Retained earnings -176.62M -157.56M -163.08M -163.08M -0.15M
Other liab - - - - 4.09M
Other assets - - - - 0.03M
Cash 54.42M 9.05M 40.46M 40.46M 0.03M
Total current liabilities 5.68M 53.21M 5.75M 5.75M 0.01M
Current deferred revenue - - 1.34M 1.34M 0.00M
Net debt - 42.57M -39.57M -39.57M -0.03M
Short term debt - 51.28M 0.25M 0.25M 0.00M
Short long term debt - 51.01M - - -
Short long term debt total - 51.62M 0.89M 0.89M 0.00M
Other stockholder equity - 320.89M 314.42M 314.42M 0.31M
Property plant equipment - - - - 1.80M
Total current assets 143.22M 162.58M 157.11M 157.11M 0.16M
Long term investments 10.91M 54.93M - 2.70M 2.70M
Net tangible assets - - - - 151.81M
Short term investments 87.51M 152.99M 115.26M 115.26M 0.01M
Accounts payable 0.79M 0.55M 2.17M 2.17M 0.00M
Non currrent assets other - 0.03M 0.02M 0.02M -0.16M
Non current assets total 12.06M 57.97M 4.53M 4.53M -0.16M
Capital lease obligations 0.37M 0.61M - 0.89M 0.89M
Breakdown 2024-12-31 2023-12-31 2023-08-31 2022-12-31 2022-08-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2023-08-31 2022-12-31 2022-08-31
Investments 105.82M -73.04M - 30.21M 30.69M
Change to liabilities - - - - -1.08M
Total cashflows from investing activities - - - - 30.21M
Total cash from financing activities -52.04M 51.98M 10.78M 10.78M 10.78M
Change to operating activities - - - - 0.14M
Net income -19.06M 5.09M -37.76M -37.76M -36.56M
Change in cash 45.37M -31.41M 13.01M 13.01M 13.01M
Begin period cash flow 9.05M 40.46M 27.46M 27.46M 27.46M
End period cash flow 54.42M 9.05M 40.46M 40.46M 40.46M
Total cash from operating activities -8.41M -10.29M -27.92M -27.92M -27.92M
Issuance of capital stock 0.00M 2.43M - 11.50M 11.50M
Depreciation 0.19M 0.20M 0.06M 0.06M 0.06M
Other cashflows from investing activities - - - 0.03M -0.00M
Sale purchase of stock -2.48M 0.00M - - -
Other cashflows from financing activities - -73.04M -0.72M -0.72M -
Change to netincome - - - - 9.53M
Capital expenditures 0.02M 0.25M 0.50M 0.50M 0.50M
Change in working capital 3.20M -2.70M -0.94M -0.94M -0.94M
Stock based compensation 4.05M 4.21M 11.51M 11.51M 11.51M
Other non cash items -1.46M -17.09M -0.78M -0.78M 0.02M
Free cash flow -8.43M -10.55M -28.41M -28.41M -28.41M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ORMP
Oramed Pharmaceuticals Inc		 -0.03
0.77%		 3.86 - - 44.00 0.62 2.86 0.52
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

1185 Avenue of the Americas, New York, NY, United States, 10036

844 967 2633

https://www.oramed.com

Name Title Year Born
Mr. Nadav Kidron Esq. Pres, CEO & Exec. Chairman 1974
Mr. David Silberman CPA CFO & Treasurer 1984
Mr. Joshua Hexter Chief Operating & Bus. Officer 1970
Dr. Miriam Kidron Ph.D. Chief Scientific Officer & Director 1940
Mr. Michael Rabinowitz Chief Commercial Officer 1965
Mr. Netanel Derovan Chief Legal Officer & Company Sec. 1975
Dr. Roy Eldor M.D., Ph.D. Chief Medical Advisor & Member of the Scientific Advisory Board NA
Mr. Nadav Kidron Esq. President, CEO & Executive Chairman 1974
Mr. Joshua Hexter Chief Operating & Business Officer 1970
Mr. Avraham Gabay CFO, Treasurer & Secretary 1986

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…